Pharming Group reports Q4 revenue of $106.5m, reaffirms 2026 guidance
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil prices rise 6% on Iraq tanker attacks, Oman port disruption Oil spikes above $100 a barrel; Adobe to report - what’s moving markets Gold prices dip below $5,200/oz as Iran war boosts oil, dollar Bank of America 2026 oil outlook: New price target issued 🎯 (South Africa Philippines Nigeria) 🎯 Pharming Group reports Q4 revenue of $106.5m, reaffirms 2026 guidance By Editor Maria Ponnezhath Stock Markets Editor Maria Ponnezhath Published 03/12/2026, 05:14 AM Pharming Group reports Q4 revenue of $106.5m, reaffirms 2026 guidance 0 PHAR -0.95% Investing.com -- Pharming Group NV (NXT AM:PHARM) reported fourth quarter revenue of $106.5 million, representing a 15% increase year-over-year, according to Thursday’s results. Full-year revenue reached $376 million, marking 26% growth compared to 2025. Ruconest sales totaled $87 million in the fourth quarter, up 9% year-over-year. Joenja sales came to $20 million in the quarter, increasing 52% year-over-year and 31% quarter-over-quarter. The company added four US patients on paid Joenja therapy during the fourth quarter, bringing the total to 120 patients as of December 31, 2025. For the full year, Pharming added 24 patients on paid therapy, compared to 16 patients in 2024. The company identified an additional 40 US patients diagnosed with APDS in 2025, versus 18 in 2024. Pharming reported increased demand in international markets, including uptake in the United Kingdom following the April 2025 launch. Fourth quarter operating profit reached $6.2 million, bringing full-year operating profit to $25.8 million. Total operating expenses of $311 million exceeded the company’s prior guidance range of $304 million to $308 million. Cash and cash equivalents stood at $181 million at the end of December 2025, which included $55 million in net cash flow from operations. For fiscal year 2026, Pharming expects total revenues between $405 million and $425 million, implying 8% to 13% ...
Read full article at source